Catalyst Funds Management Pty Ltd Takes $268,000 Position in IDEXX Laboratories, Inc. $IDXX

Catalyst Funds Management Pty Ltd acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 500 shares of the company’s stock, valued at approximately $268,000.

A number of other large investors have also recently bought and sold shares of the business. Mutual of America Capital Management LLC raised its holdings in shares of IDEXX Laboratories by 79.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock worth $8,160,000 after purchasing an additional 8,609 shares in the last quarter. Arkadios Wealth Advisors bought a new stake in IDEXX Laboratories during the second quarter worth approximately $405,000. Plato Investment Management Ltd grew its position in IDEXX Laboratories by 37.1% in the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock worth $1,310,000 after buying an additional 835 shares during the last quarter. Genesis Wealth Advisors LLC bought a new position in shares of IDEXX Laboratories in the second quarter valued at $215,000. Finally, ORG Wealth Partners LLC bought a new position in shares of IDEXX Laboratories in the second quarter valued at $273,000. Institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.98% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on IDXX shares. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. UBS Group increased their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research note on Monday, November 3rd. Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, JPMorgan Chase & Co. raised their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $730.50.

IDEXX Laboratories Stock Up 5.3%

IDEXX Laboratories stock opened at $725.91 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $735.59. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The firm has a market cap of $57.96 billion, a PE ratio of 60.44, a P/E/G ratio of 4.06 and a beta of 1.62. The firm’s 50 day moving average price is $656.12 and its two-hundred day moving average price is $595.80.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the company posted $2.80 EPS. IDEXX Laboratories’s revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.